GLP-1 weight loss looks great on the scale, but the scale can’t tell fat from muscle. Research from early 2026 found that without a deliberate strategy, up to 40% of the weight lost on GLP-1 medication can come from lean muscle tissue, not fat.

In clinical terms this pattern is sometimes called sarcopenic obesity, and with newer, higher-dose GLP-1 compounds, that proportion can climb even higher. The intense appetite suppression these drugs cause often means people simply aren’t eating enough protein to protect what they have.

The good news is this isn’t inevitable. It’s largely a function of what you eat and whether you’re training, both of which are within your control.

It’s not all bad news. A 2026 study published in Cell Reports Medicine looked at both obese mice and a proof-of-concept human trial, and found that GLP-1 medicines predominantly reduce body fat over lean body mass, with muscle strength relatively preserved despite a modest decrease in muscle size.

Interestingly, the same research found that loss of liver mass actually exceeded the change in muscle mass among lean tissues. And while absolute muscle size went down slightly, relative muscle mass and strength actually improved, which translated into better running performance in the animal studies.

So the body is, to some extent, preferentially burning fat. The muscle loss that does happen is a secondary effect that gets worse without intervention, not the primary mechanism of the drug.

Here’s why this isn’t just about how you look. At the 2026 American Diabetes Association Scientific Sessions, one researcher put hard numbers on it: each kilogram of muscle mass lost reduces resting energy expenditure by about 13 kilocalories, compared with only 4 kilocalories for a kilogram of fat.

That means muscle is doing more work per pound to keep your metabolism running than fat does. Lose enough of it, and maintaining your new weight gets noticeably harder, even if your calorie intake stays the same.

This is the real reason preserving lean mass during GLP-1 weight loss matters for the long run, not just for strength or appearance, but for whether the weight loss actually sticks.

Protein recommendations vary a bit across the literature, but the practical range that keeps showing up is consistent. Recent clinical reviews point to roughly 1.2 to 1.6 grams of protein per kilogram of body weight per day as the effective range, with diminishing returns above that threshold.

The distribution matters as much as the total. Your body can only use so much protein at once for muscle synthesis, so spreading intake across meals works better than front-loading it. Aim for around 25-30 grams of protein per meal rather than one large protein-heavy dinner.

Leucine-rich sources like lean meats, eggs, and dairy are particularly useful here, since leucine is one of the amino acids that directly triggers muscle protein synthesis.

If protein is the most important nutritional piece, resistance training is the most important behavioral one. A clinical trial combining a GLP-1 drug with supervised resistance and aerobic training didn’t just produce better weight loss results, it actually allowed patients to gain lean mass, something pharmacotherapy alone never achieved.

An even more striking result came from a phase 2 trial combining semaglutide with a muscle-targeting compound: the lean mass fraction of total weight loss dropped from roughly 21% down to just 7% when muscle-focused intervention was added.

You don’t need that level of pharmacology to see a benefit, though. Consistent resistance training two to three times a week, even with modest loads, is the behavioral equivalent that’s available to anyone right now.